Condition
Crohn's disease news across medications, symptoms, tests, procedures, complications, research, access, and daily life.
Page 4 of 53 · 2513 articles
People with Crohn’s or IBD often try nutritional supplements; this article surveys claims and early research about collagen peptides that some hope could support gut lining and reduce inflammation. It’s useful for...
Longer-term and real-world data help patients and clinicians understand how well risankizumab and upadacitinib maintain clinical and endoscopic improvement over years of treatment, and early data on an investigational...
MRE is a widely used, noninvasive test that increasingly helps characterize disease phenotype and prognosis in Crohn's disease and IBD, which can affect monitoring and treatment planning.
MRE is a key, non-radiating test for Crohn’s disease that can show active inflammation and complications that endoscopy may miss, so updates on technique matter for diagnosis and monitoring. Better imaging technique can...
Patients and clinicians use the term "disease burden" to describe more than inflammation alone; it affects symptoms, daily function, mental health, and healthcare use. A clearer, integrated way to measure burden could...
Vitamin D deficiency was very common in this IBD cohort and was linked to Crohn’s disease and female sex, which may matter because deficiency can affect bone health and immune regulation in people with IBD.
Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Crohn's disease, Inflammatory bowel disease, and Biomarkers. The original article is from Frontiers in medicine.
Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab. Open the original article for the full details.
Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Inflammatory bowel disease, and Complications. The original article is from Respiratory medicine case reports.
The findings suggest that tissue-based immune profiling may better identify biologically distinct subgroups in ulcerative colitis than blood tests, which could affect research on personalized treatment or trial...
If replicated and confirmed, the genetic evidence that shorter telomeres increase risk of fibrotic lung disease (IPF) helps clarify that telomere length itself — not just telomerase-pathway genes — may be relevant to...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Mirikizumab, and IL-23 inhibitor. The original article is from JMA journal.
This study aims to show how mirikizumab and other biologics perform in everyday community practice — information that can help clinicians and patients understand real-world treatment durability, symptom control, and...
Fundraisers like this support research, education, advocacy, and patient programs that can benefit people with Crohn’s disease and other forms of IBD. The story also raises awareness by centering a public figure who...
A Phase 3 study is testing whether upadacitinib is safe and effective for children with moderate-to-severe Crohn's disease who have not responded to or cannot take other therapies. Positive results could expand treatment...
If reliable, blood biomarkers that track IBD activity could help noninvasively follow children with Crohn’s disease or ulcerative colitis. This study suggests MMP-9 and TIMP-1 change with disease course but did not show...
A blood biomarker that reflects transmural inflammation could help monitor small-bowel Crohn’s disease noninvasively and might predict risk of rehospitalization.
A registry focused on "difficult-to-treat" IBD aims to describe how often and why patients become treatment-refractory, how their disease and treatments evolve over time, and which outcomes (hospitalization, surgery,...
Cardiovascular disease is an important extraintestinal concern for people with IBD, and current risk scores may miss IBD-specific drivers. This study aims to track heart and vascular events in IBD and find biomarkers...
People with Crohn’s disease or ulcerative colitis may have higher cardiovascular risk; this prospective study aims to measure how often major heart and vascular events occur in IBD and to find biological and clinical...
First-person stories can help people with Crohn’s disease feel less alone and show ways to turn a diagnosis into advocacy or research involvement. The article highlights pediatric-to-adult transition issues and patient...
Predicting early need for infliximab could help identify children with Crohn’s disease who may benefit from earlier biologic therapy instead of prolonged conventional treatment. A reliable prediction tool may shorten...
IL-11 is implicated in fibrostenotic Crohn’s disease; determining whether it is a reversible therapeutic target could lead to treatments that prevent or reverse strictures rather than only managing inflammation or...
Patients with IBD have an increased colorectal cancer risk, and those with PSC, extensive colitis, severe inflammation, or prior dysplasia are at especially high risk. High-quality surveillance techniques can improve...
Based on the title and source metadata, this appears to be a conference abstract related to Crohn's disease, Inflammatory bowel disease, and Microbiome. The original article is from Anais do XI Congresso Médico...
Real-world data on upadacitinib help patients and clinicians understand how the drug performs outside clinical trials, including how long patients stay on treatment, remission rates, and common side effects.
The report suggests fertility treatments—particularly embryo transfer/IVF—can be successful for many women with Crohn's disease or ulcerative colitis, which may reassure patients concerned about fertility after IBD or...
This story highlights fundraising and awareness activities for the Crohn’s & Colitis Foundation, showing how public figures with IBD can help raise funds and visibility for the community.
The study provides first human evidence that a single colonoscopic FMT can eradicate mucosal adherent-invasive E. coli (AIEC), a bacterium linked to Crohn’s disease, and it shows associated shifts in mucosal microbiota...
Fundraising events support research, education, advocacy, and direct patient services that can benefit people living with Crohn’s disease and other forms of IBD. A public figure with lived experience being honored can...
Company-reported one-year results suggest mirikizumab (Omvoh), an IL-23p19 inhibitor, can achieve multi-dimensional treatment goals including symptom control, quality-of-life improvement, and steroid-free deep remission...
Support organizations can offer education, peer connection, mental-health services, advocacy, and programs for children and families that complement medical care. Knowing where to find these resources can help people...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Ct Enterography. The original article is from idp.springer.com.
Deep remission is an emerging treatment target in Crohn’s disease that combines symptoms and objective measures. A meaningful proportion of patients in VIVID-1 achieved corticosteroid-free deep remission with mirikizumab...
The article reports Phase 3 post‑hoc analyses showing that mirikizumab (Omvoh) produced higher rates of composite, multidimensional remission measures in UC and Crohn’s disease versus placebo, which could matter to...
Phase 3 results suggest mirikizumab (Omvoh) can produce sustained, steroid-free remission-related outcomes at one year in both ulcerative colitis and Crohn’s disease, including in some patients who previously failed...
New one-year trial analyses suggest mirikizumab (Omvoh) may help more people with moderate-to-severe ulcerative colitis or Crohn’s disease reach combined clinical and endoscopic goals and reduce steroid dependence.
These results suggest mirikizumab can achieve multiple treatment goals at once — symptoms, objective inflammation measures, and steroid-free status — outcomes that matter to people with IBD because they reflect both...
This study connects USP25 to NOD2–XIAP signaling and Crohn’s disease genetics, suggesting a possible target for future therapies or biomarkers relevant to IBD pathogenesis.
MMP-2 regulates tissue remodeling and inflammation in IBD; targeting it might help prevent barrier damage, chronic inflammation, or fibrosis but requires selective approaches to avoid harming normal repair processes.
Based on the title and source metadata, this appears to be a case report related to Crohn's disease and Research and clinical trials. The original article is from Updates in surgery.
This study explores a non-drug dietary supplement approach aimed at changing host–microbiome interactions after surgery — a potentially relevant prevention strategy for postoperative Crohn's disease recurrence if later...
Findings highlight cultivable gut microbiota differences in Crohn’s disease versus controls and present preliminary in vitro antimicrobial activity of two thyme essential oils—topics that may interest patients following...
Microbiota-derived metabolites are linked to inflammation and gut barrier function, so they could become biomarkers or therapeutic targets for Crohn’s disease and ulcerative colitis. Patients may see future tests or...
Findings suggest GM-CSF signaling may help limit epithelial injury and shape immune cell states in Crohn’s disease, which could be relevant to understanding inflammation and future therapies targeting innate immunity or...
Many people with Crohn’s disease or ulcerative colitis use biologic drugs; new clinical and real-world data about a subcutaneous infliximab option could affect treatment choice, switching decisions, and practical use in...
Protein biomarkers that predict IBD years before diagnosis could enable earlier detection, inform risk-stratified monitoring, and reveal early disease pathways that might be targeted to prevent or delay onset.
Muscle loss (myopenia) can persist in Crohn's disease even after weight recovery and clinical remission, which may affect long-term outcomes. Identifying persistent muscle depletion with body composition measures could...
